Effect of Empagliflozin on Inflammation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT07292909
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Hotel Dieu de France Hospital
- Registry
-
NCT07292909
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Lebanon
- Registry status
- Recruiting
Technical summary
Registry record NCT07292909. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-01 (actual); primary completion 2027-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Empagliflozin on Inflammation
- Acronym
- EMPANTINFLAM
- Condition
- Inflamation
- Condition
- SGLT 2 Inhibitors
- Intervention (Drug)
- Empagliflozin (SGLT2i)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hotel Dieu de France Hospital
Record details
- Record id
cardio:ct-nct07292909- Content hash
5079d778e9a3ad77ea9c0b7db6bbc598c025e1267a92171ab6ec378c26246363